Anti-tumor immune reactions are recovered by the blockade of PD-1 pathway and subsequent therapeutic benefits are achieved in certain non-hematopoietic solid tumors and in Hodgkin’s lymphoma26. The gene discussed is PDCD1; the disease is neoplasm.